Johnson & Johnson Eyes $20 Billion Orthopedics Sale Amid Portfolio Shift
Johnson & Johnson's (ISIN US4781601046) stock price has been closely watched as talks of a potential divestment of its orthopedics business have emerged. The company is reportedly in negotiations to sell its DePuy Synthes business, valued at around $20 billion, to Apollo Global Management. This move would signify a significant rebalancing of Johnson & Johnson's medtech portfolio.
According to GuruFocus, the deal value for the DePuy Synthes orthopedic division is around $20 billion, leaving room for other bidders to enter the process. Simply Wall St notes that this potential transaction would be part of a broader medtech shift by Johnson & Johnson, positioning the company to focus on higher-growth medical technology areas.
Johnson & Johnson's stock price has been trading close to $266 on the New York Stock Exchange as of September 12, 2026. The company's market capitalization is around $640 billion, underlining the scale of the healthcare group. However, GuruFocus calculates a GF Value of $193.26 for Johnson & Johnson compared with its current share price of $265.58, implying that the stock trades about 37.4% above this intrinsic value estimate.